Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

In an “urgent medical device correction,” the company urges clinicians to remind patients to monitor their glucose levels during takeoffs and landings.

Baird last night initiated coverage of Beta Bionics (BBNX) with a Neutral rating and $20 price target The firm believes Beta’s iLet Bionic ...

Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With ...

Looking ahead, Insulet provided a strong outlook for 2025, projecting total revenue growth of 16% to 20% in constant currency. The company expects U.S. Omnipod revenue to grow 16% to 20% and ...

The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...